Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

SERRETTA, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.821
EU - Europa 11.768
AS - Asia 8.945
SA - Sud America 1.314
AF - Africa 247
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 12
Totale 40.138
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.528
RU - Federazione Russa 3.366
SG - Singapore 3.175
CN - Cina 2.274
IT - Italia 2.130
FI - Finlandia 1.150
BR - Brasile 1.055
DE - Germania 1.048
UA - Ucraina 1.009
HK - Hong Kong 896
VN - Vietnam 825
IE - Irlanda 596
PL - Polonia 575
GB - Regno Unito 525
FR - Francia 458
SE - Svezia 379
BD - Bangladesh 375
JP - Giappone 359
IN - India 211
KR - Corea 206
CA - Canada 146
BE - Belgio 100
RO - Romania 96
IQ - Iraq 94
AR - Argentina 89
NL - Olanda 78
MX - Messico 77
CI - Costa d'Avorio 69
TR - Turchia 65
AT - Austria 57
ZA - Sudafrica 53
PK - Pakistan 52
VE - Venezuela 46
ES - Italia 45
UZ - Uzbekistan 43
ID - Indonesia 42
CH - Svizzera 37
MY - Malesia 34
AE - Emirati Arabi Uniti 31
CZ - Repubblica Ceca 31
CO - Colombia 30
EC - Ecuador 30
PH - Filippine 30
CL - Cile 28
SA - Arabia Saudita 27
AU - Australia 26
EG - Egitto 25
MA - Marocco 25
JO - Giordania 21
IL - Israele 18
IR - Iran 18
AZ - Azerbaigian 17
KZ - Kazakistan 16
TN - Tunisia 16
DZ - Algeria 14
LB - Libano 14
KE - Kenya 13
NP - Nepal 13
PY - Paraguay 13
AL - Albania 12
BH - Bahrain 12
GR - Grecia 12
JM - Giamaica 12
LT - Lituania 12
GE - Georgia 11
RS - Serbia 10
CR - Costa Rica 9
OM - Oman 9
TH - Thailandia 9
TW - Taiwan 9
UY - Uruguay 9
HN - Honduras 8
AO - Angola 7
BB - Barbados 7
BG - Bulgaria 7
NG - Nigeria 7
PA - Panama 7
PE - Perù 7
BO - Bolivia 6
EU - Europa 6
KW - Kuwait 6
MD - Moldavia 6
PS - Palestinian Territory 6
PT - Portogallo 6
AM - Armenia 5
DO - Repubblica Dominicana 5
NZ - Nuova Zelanda 5
ET - Etiopia 4
NI - Nicaragua 4
SY - Repubblica araba siriana 4
XK - ???statistics.table.value.countryCode.XK??? 4
BA - Bosnia-Erzegovina 3
BN - Brunei Darussalam 3
BY - Bielorussia 3
CM - Camerun 3
DK - Danimarca 3
GT - Guatemala 3
KG - Kirghizistan 3
KH - Cambogia 3
LU - Lussemburgo 3
Totale 40.089
Salva come PNG Salva come JPEG
Città #
Ashburn 2.386
Singapore 2.049
Fairfield 1.631
Chandler 1.084
San Jose 1.060
Woodbridge 867
Hong Kong 847
Wilmington 822
Ann Arbor 759
Houston 703
Seattle 638
Dublin 594
Jacksonville 530
Cambridge 515
Zgierz 511
Moscow 427
Medford 415
Beijing 397
Tokyo 339
Des Moines 284
New York 278
Santa Clara 277
Nanjing 275
Ho Chi Minh City 268
Frankfurt am Main 266
Princeton 266
Los Angeles 252
Lauterbourg 221
Boardman 215
Hanoi 203
Palermo 189
Helsinki 182
Council Bluffs 181
Dallas 178
Altamura 171
The Dalles 161
Hefei 157
Tulsa 148
Lawrence 137
Buffalo 129
Milan 129
Dearborn 122
Nanchang 108
San Diego 107
Brussels 98
São Paulo 98
Shenyang 92
Chicago 78
Hebei 73
Rome 71
Changsha 70
Orem 70
Abidjan 69
Tianjin 65
Jiaxing 62
Ludwigshafen am Rhein 61
Nuremberg 61
Columbus 58
London 55
Munich 52
Da Nang 50
Guangzhou 47
Seongnam 46
Jinan 45
Montreal 45
Kumar 43
Saint Petersburg 43
Amsterdam 41
Verona 40
Toronto 39
Warsaw 39
Denver 38
Zhengzhou 38
Redwood City 37
Haiphong 36
Venice 36
Chennai 35
Baghdad 34
Bremen 34
Brooklyn 34
Tashkent 34
Nave 33
Auburn Hills 30
Rio de Janeiro 30
Seoul 30
Belo Horizonte 29
Johannesburg 29
Phoenix 27
Falls Church 26
Ningbo 26
San Mateo 26
Manchester 25
San Paolo di Civitate 25
Atlanta 24
Boston 24
City of London 23
Paris 23
Dhaka 22
Mumbai 22
Poplar 22
Totale 23.941
Salva come PNG Salva come JPEG
Nome #
S9-Fibronectin, EGF-R, HB-EGF:biomarkers of urothelial damage during intravesical adjuvant therapy? 574
Clinical and biochemical markers of visceral adipose tissue activity: Body mass index, visceral adiposity index, leptin, adiponectin, and matrix metalloproteinase-3. Correlation with Gleason patterns 4 and 5 at prostate biopsy 343
Characterization of human infiltrating and circulating gamma-delta t cells in prostate cancer 302
Drinking water source and cigarette smoking in transitional cell carcinoma of the bladder. 287
Manuale di Urologia e Andrologia. Capitolo 1: Anatomia dell'apparato genito-urinario 284
Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study 282
A phase I-II study on intravesical Gemcitabine in superficial bladder papillary tumors 280
A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. 279
Whatsapp messenger as a tool for the multidisciplinary management in everyday clinical practice 267
Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. 265
Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma 260
Cytokine gene expression in the tunica albuginea 
of patients with Peyronie’s disease. Pilot study with 
a control group 245
Modificazioni del PSA dopo terapia antibiotica in pazienti candidati alla biopsia prostatica. 236
Segmental resection of distal ureter with termino-terminal ureteric anastomosis vs bladder cuff removal and ureteric re-implantation for upper tract urothelial carcinoma: results of a multicentre study 232
Cytokines gene expression in the tunica albuginea of patients with Peyronie’s disease. Pilot study with a control group 229
PROSPECTIVE, RANDOMIZED, CROSSOVER COMPARISON OF SUBLINGUAL APOMORPHINE (3 mg) WITH ORAL SILDENAFIL (50 mg) FOR MALE ERECTILE DYSFUNCTION 221
Il carcinoma prostatico in Calabria e Sicilia. 220
Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy 219
Clinical implications of a rare renal entity: Pleomorphic Hyalinizing Angiectatic Tumor (PHAT) 218
Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes 216
Preliminary report of a multicentric study on environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder 215
A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. 214
WHATSAPP MESSENGER AS A REAL-TIME TOOL FOR A LONG-DISTANCE ACTIVITY OF A MULTIDISCIPLINARY 214
Cytokines gene expression in the tunica albuginea in patients with Peyronie’s disease. Pilot study with a control group 210
Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials? 210
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder 210
Analisi preliminare dei fattori demografici ed eziopatogenetici in pazienti affetti da carcinoma vescicale a medio rischio di recidiva 209
POSITIVITA’ DELL’NMP22 E NEGATIVITA’ CISTOSCOPICA E CITOLOGICA. QUALE SIGNIFICATO ATTRIBUIRE? 206
Valore clinico della riduzione del PSA in soggetti candidati all’agobiopsia prostatica 206
Mitomycin C from birth to adulthood 205
Recurrence and progression according to stage at re-TUR in t1g3 bladder cancer patients treated with BCG: Not as bad as previously thought 205
Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder: Phase I-II study on marker lesions 204
The activity of intravesical hyaluronic acid and chondroitin sulfate administration on urothelial gene expression. Preliminary results on the epidermal growth factor receptor and fibronectin gene expression evaluated in bladder washings of patients affected by non muscle-invasive bladder cancer 204
La terapia dei tumori vescicali superficiali: lo stato attuale 202
How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency? 202
TERAPIA CONSERVATIVA DELL'UROTELIOMA VESCICALE T1G3. RISULTATI SU 235 PAZIENTI 201
Management of bicalutamide induced gynaecomastia. A randomized study comparing therapy versus prophylaxis with tamoxifen. 201
Fumo, risorsa idrica ed altri fattori di rischio nel carcinoma vescicale superficiale 200
Sarcomatoid carcinoma of urinary bladder: Immunohistochemical study of an uncommon case 200
Genitourinary Symptoms-Patient Help-Seeking and General Practitioner Management: An Outpatient Based Survey at a Tertiary Hospital in Southern Italy 199
Carcinoma uroteliale in cisti pielogena 198
Distribution of smoking, water resource and other environmental factors in patients affected by superficial bladder cancer 195
Intravesical gemcitabine in superficial bladder tumours preliminary results of a phase I-II study 194
Correlation between BMI and the pathological features of prostate cancer at biopsy 194
La p53 nel tumore vescicale superficiale (Ta-T1, G1-3) 192
Chemioterapia adiuvante e fattori di rischio ambientale nel carcinoma vescicale superficiale a medio rischio di recidiva. Uno studio prospettico randomizzato del Gruppo Studio Tumori Urologici (GSTU). 192
INTRAVESICAL GEMCITABINE IN SUPERFICIAL BLADDER TUMOURS.RESULTS OF A PHASE I-II STUDY 191
PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients 190
Multiplicity and history have a detrimental effect on survival in patients with T1G3 bladder tumors selected for conservative treatment. 190
Re: Urinary pH is Highly Associated With Tumor Recurrence During Intravesical Mitomycin C Therapy for Nonmuscle Invasive Bladder Tumor 190
T1HG Bladder Tumours: So Many Papers, Do We Need Them? Yes, We Do! 189
Chemioterapia adiuvante e fattori di rischio ambientale nel carcinoma vescicale superficiale a medio rischio di recidiva. Uno studio prospettico randomizzato del Gruppo Studi Tumori Urologici (GSTU) 187
Does Exist A Correlation Between BMI and Gleason Patterns 4 and 5 At Prostate Biopsy? 187
Fumo di sigaretta e risorsa idrica in pazienti affetti da carcinoma vescicale superficiale. XV Congresso Nazionale SIUro, Giardini Naxos 3-6 novembre 2005. 1. 186
Ruolo prognostico della p53 nel tumore vescicale superficiale. Correlazione con recidiva e progressione – 186
IS VISCERAL ADIPOSITY INDEX (VAI)RELATED TO PROSTATE CANCER DETECTED BY BIOPSY? 185
BIOMARKERS OF UROTHELIAL DAMAGE IN PATIENTS TREATED BY ADJUVANT INTRAVESICAL THERAPY 184
Fibronectin (FN), epidermal growth factor-receptor (EGF-R) and heparin-binding epidermal growth factor-like (HB-EGF) urinary expressions and topical toxicity of adjuvant intravesical therapy for non muscle invasive bladder cancer (NMI-BC) 184
Attività lavorativa e fattori di rischio ambientale in pazienti affetti da carcinoma vescicale superficiale. 183
Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression 183
Modificazioni del PSA dopo terapia antibiotica in pazienti candidati alla biopsia prostatica 182
Plasma levels of angiogenetic markers in men candidate to prostate biopsy 182
The clinical value of PSA increase during intravesical adjuvant therapy for nonmuscle-invasive bladder cancer. 182
Fattori di rischio ambientali nella storia naturale del carcinoma vescicale superficiale. 181
PROSTATA (PROSTATITI, IPERTROFIA PROSTATICA, CANCRO DELLA PROSTATA) 181
The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer 181
High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study 181
Segmental ureterectomy vs. radical nephroureterectomy for ureteral carcinoma in patients with a preoperative glomerular filtration rate less than 90 ml/min/1.73 m2: A multicenter study 181
Studio pilota sul valore predittivo dei livelli plasmatici di 9 fattori angiogenetici nella selezione di pazienti candidati alla biopsia prostatica 179
Correlation between chronic prostatitis syndrome and pelvic venous disease. A survey of 2554 urologic outpatients 178
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer 178
Fattori di rischio ambientale nel carcinoma vescicale superficiale. Risultati su 577 pazienti sottoposti a chemioterapia endovescicale adiuvante 177
Studio randomizzato sul ruolo del mantenimento nella chemioprofilassi endovescicale precoce dopo TUR con Epirubicina. XVI Congresso Nazionale Società Italiana di Urologia Oncologica. 30 Novembre - 3 Dicembre 2006. Arch. Ital. Urol. Androl. vol. , pp. 71. ISBN/ISSN: 1124-3562. 176
Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer 175
TUR AND ADJUVANT INTRAVESCICAL CHEMOTHERAPY IN T1G3 BLADDER TUMORS. RECURRENCE, PROGRESSION AND SURVIVAL IN 137 SELECTED PATIENTS FOLLOWED UP TO 20 YEARS. 175
CHEMIOPROFILASSI PRECOCE CON EPIRUBICINA AD ALTA DOSE NEL CARCINOMA VESCICALE SUPERFICIALE. STUDIO RANDOMIZZATO DEL GSTU 175
Cigarette Smoking Status at Diagnosis and Recurrence in Intermediate-risk Nonemuscle-invasive Bladder Carcinoma 175
Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the vesical antiblastic therapy Italian study 174
Although rare, severe complications following intravesical bacillus Calmette-Guerin treatment should not be overlooked! 174
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer 174
Intravesical gemcitabine is superficial bladder tumours. Results of a phase I-II study 173
Compliance to therapy with Dapoxetine in comparison to a conventional selective serotonin reuptake inhibitor (Citalopram) in 118 patients with premature ejaculation. 173
Water Chlorination and other environmental factors in bladder cancer. Result of a multicentre study. 172
Can we clinically distinguish anejaculation from retrograde ejaculation in patients on α1A-blockers therapy for lower urinary tract symptoms? 172
Efficacia del mantenimento nella chemioprofilassi endovescicale precode dopo TUR. Risultati di uno studio randomizzato multicentrico. 171
Survival risk factors in T1G3 non-muscle-invasive (NMI) bladder cancer consevatively treated. Long term results. 171
A RANDOMIZED STUDY EVALUATING MAINTENANCE SCHEDULE IN EARLY ADJUVANT CHEMOTHERAPY FOR INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER. 171
Acute and late toxicity and preliminary outcomes report of moderately hypofractionated helical tomotherapy for localized prostate cancer: a mono-institutional analysis 171
Cigarette smoking and drinking water source: Correlation with clinical features and pathology of superficial bladder carcinoma. 170
PSA and second-line therapy of hormone refractory prostate carcinoma 170
A case of renal carcinoma metastasis simulating a thyroid goiter 169
PLEOMORPHIC HYALINIZING ANGIOECTATIC TUMOR (PHAT) OF RENAL PARENCHYMA. FIRST CASE REPORTED IN LITERATURE 169
ESTRAMUSTINA FOSFATO VS ASSOCIAZIONE A BASSA DOSE DI ESTRAMUSTINA FOSFATO E ETOPOSIDE NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO (HRPC). STUDIO RANDOMIZZATO DI FASE II DEL GRUPPO STUDI TUMORI UROLOGICI (GSTU) 168
Chemioterapia domiciliare nel carcinoma prostatico ormonorefrattario (HRPC). Studio di fase II del gruppo studio tumori urologici (GSTU). 168
Significato clinico della positività della NMP22 in pazienti in follow-up per carcinoma vescicale superficiale. Risultati a lungo termine 168
A randomized phase II study of estramustine phosphate versus estramustine phosphate plus etoposide in hormone refractory prostate cancer (HRPC). 168
Fattori di rischio ambientale nel carcinoma vescicale superficiale. Risultati su 577 pazienti sottoposti a chemioterapia endovescicale adiuvante. 167
Impact of stage migration on bladder cancer: A slow but steady improvement in the long term survival rates after radical cystectomy in the last 25 years 167
STUDIO RANDOMIZZATO SUL RUOLO DEL MANTENIMENTO NELLA CHEMIOPROFILASSI ENDOVESCICALE PRECOCE DOPO TUR CON EPIRUBICINA 166
FOLLOW UP A LUNGO TERMINE DI PAZIENTI CON POSITIVITA’ DELLA NMP22 E NEGATIVITA’ CISTOSCOPICA E CITOLOGICA 166
Totale 20.307
Salva come PNG Salva come JPEG
Categoria #
all - tutte 134.089
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 134.089
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021373 0 0 0 0 0 0 0 0 0 0 0 373
2021/20222.688 126 575 61 140 150 115 73 142 332 331 108 535
2022/20233.769 418 549 89 334 406 498 226 238 800 21 137 53
2023/20241.735 71 237 170 180 151 357 153 124 11 21 75 185
2024/20254.105 138 212 194 370 202 153 258 294 359 430 616 879
2025/202615.555 1.105 464 788 1.017 1.319 2.389 2.290 1.629 1.136 2.150 815 453
Totale 40.973